Joseph G. Pressey · Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.
Follow
Article1 min read·Published Nov 2026

Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Nov 2026 · 1 min read

In brief

In brief

This case report describes severe cytokine release syndrome occurring after PD-1 checkpoint inhibitor therapy in a young patient with alveolar soft part sarcoma. The presentation highlights an uncommon but serious immune-related adverse event associated with checkpoint blockade immunotherapy.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Cytokine release syndrome (CRS) is a phenomenon of immune hyperactivation described in the setting of cellular and bispecific T-cell engaging immunotherapy. Checkpoint blockade using anti-programmed cell death 1 (anti-PD-1) inhibitors is an approach to antitumor immune system stimulation. A 29-year-old female with alveolar soft part sarcoma developed severe CRS after treatment with anti-PD-1 thera…

Statements in this article

  1. Cytokine release syndrome is a phenomenon of immune hyperactivation described in the setting of cellular and bispecific T-cell engaging immunotherapy.

    Established
  2. Severe cytokine release syndrome can occur in patients receiving anti-PD-1 checkpoint blockade therapy.

    Research

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.